An interventional study of Topical Ophthalmic Cooling in Eye Pain, sponsored by EyeCool Therapeutics, Inc.. Recruiting at 1 site in Australia. Open to participants aged 22 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-05-26.
Sponsored by EyeCool Therapeutics, Inc. · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of this clinical trial is to understand what effect a cold treatment with an investigational device, ETX-4143, has on the anatomical structures and the inflammatory response of the surface of the eye in those people who suffer from chronic ocular surface pain (COSP). The trial will also tell us more about the safety of this investigational device. The main questions this study aims to answer are:
Researchers will obtain images of the corneal surface nerves for analysis using a confocal microscope and collect tear bio samples for analysis.
Participants will:
EyeCool Therapeutics was founded on the hypothesis that a mild ocular surface cooling treatment, delivered through its proprietary cooling device (ETX-4143), can improve the symptoms of chronic ocular surface pain by transiently inhibiting nerve signaling, and potentially reducing ocular surface inflammation, and potentially restoring normal ocular surface nerve function.
The ETX-4143 Device is a handheld medical device that contains an internal frozen (-20° Centigrade) mixture of purified water and glycerol. The ETX-4143 Device does not contain an active pharmaceutical ingredient. The frozen mixture internally cools two metallic probes that contact the conjunctival surface of the patient; there is no direct contact of the ocular surface with the frozen mixture. Prior to placement of the device on the ocular surface, local anesthesia is administered and a custom speculum used to open and insulate the eyelids, as well as promote correct positioning of the Device. A cornea shield is applied to maintain corneal wetness during the procedure. The Device and accessory (speculum) are provided in disposable, single-use packaging.
In this prospective, single-center, single-center clinical study, 5 adult subjects with chronic ocular surface pain will be identified and treated with the ETX-4143 Device (Cooling Device for topical ophthalmic use). The main goal of the study is to further evaluate the device for changes in ocular surface components using in vivo confocal microscopy, and for safety and efficacy. Improvement in self-reported ocular discomfort and clinical safety measures will be evaluated, along with in vivo confocal microscopy of the cornea before and after treatment.
It is anticipated that the learnings from these observations will be used to design future studies of the ETX-4143 device. In this study, five subjects will receive the investigational product (ETX-4143 Device).
The Medical Monitor will evaluate the clinical safety data as it becomes available and no less than on at least a quarterly basis.
All subjects will be followed for a total of 12 weeks. Subjects will have only the worse eye treated, if both eyes meet the inclusion/exclusion criteria. The worse eye will be determined by the investigator based on subjective reporting from the study subject of chronic ocular surface pain and/or other screening assessments in each eye. Both eyes will be assessed for tear osmolarity and imaged using corneal in vivo confocal microscopy at the University of Melbourne, with the untreated eye representing a control.
31 studies on the registry are indexed under Eye Pain; 7 are open to participants now.
This study's planned enrollment of 5 is below the median of 55 across 28 interventional studies indexed under Eye Pain.
Browse Eye Pain studies →EyeCool Therapeutics, Inc. is the lead sponsor of 3 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Eyes that are treated with the ETX-4143 topical ophthalmic cooling device
Device: Topical Ophthalmic Cooling
Targeted topical ophthalmic cooling treatment using the ETX-4143 cooling device
Corneal Confocal In-vivo Microscopy Image Analysis
Non-invasive imaging of the corneal surface for assessing ocular tissue structure.
Time frame: From treatment to the end of twelve weeks
Plan to share: No
Started Aug 2025 (actual). Primary completion is estimated for Jul 2026, 10 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
EyeCool Therapeutics, Inc.